IndiviorINDV
INDV
About: Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Employees: 1,164
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 8 (+4) [Q4]
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
70% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 23
20% more capital invested
Capital invested by funds: $812M [Q3] → $974M (+$162M) [Q4]
9% more funds holding
Funds holding: 102 [Q3] → 111 (+9) [Q4]
8.62% more ownership
Funds ownership: 53.32% [Q3] → 61.94% (+8.62%) [Q4]
2% more call options, than puts
Call options by funds: $831K | Put options by funds: $811K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$13
15%
upside
Avg. target
$13
15%
upside
High target
$13
15%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Amsellem 53% 1-year accuracy 18 / 34 met price target | 15%upside $13 | Overweight Maintained | 6 Mar 2025 |
Financial journalist opinion
Based on 6 articles about INDV published over the past 30 days
Neutral
PRNewsWire
4 days ago
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4 th.
Neutral
PRNewsWire
2 weeks ago
New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy
SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During Pregnancy" in the American Journal on Addictions, evaluating the use of SUBLOCADE for the treatment of opioid use disorder (OUD) during pregnancy and postpartum.
Neutral
Seeking Alpha
2 weeks ago
Indivior: Trying To Break Addiction
Indivior PLC's stock has seen headwinds recently due to increasing competition and poor performance but has potential for recovery with a new CEO and strategic changes. Sublocade, Indivior's key product franchise, faces competition but shows promise with expanded FDA approval and a stabilizing market share. Despite litigation risks and financial challenges, analysts remain optimistic, projecting growth in the buprenorphine market and potential stock recovery.
Neutral
Seeking Alpha
3 weeks ago
Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript
Indivior PLC (NASDAQ:INDV ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participants Carl Burns - Northland Capital Markets David Amsellem - Piper Sandler Christian Glennie - Stifel Chase Knickerbocker - Craig-Hallum Thibault Boutherin - Morgan Stanley Paul Cuddon - Deutsche Numis Operator Good day and thank you for standing by. Welcome to the Indivior PLC Q1 2025 Financial Results Conference Call.
Positive
Zacks Investment Research
3 weeks ago
Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates
Indivior PLC (INDV) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.37 per share a year ago.
Neutral
PRNewsWire
3 weeks ago
Indivior Announces Q1 2025 Financial Results
SLOUGH, United Kingdom and RICHMOND, Va. , April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025.
Neutral
PRNewsWire
2 months ago
Indivior Announces Further Changes to Board of Directors
RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P.
Neutral
Reuters
2 months ago
UK's Indivior appoints Joe Ciaffoni as CEO
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Neutral
PRNewsWire
2 months ago
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.
Neutral
PRNewsWire
2 months ago
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va. , Feb. 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol and alternative injection sites, marking a significant advancement in the treatment of moderate to severe opioid use disorder (OUD).
Charts implemented using Lightweight Charts™